相关实验视频

Updated: Jun 15, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

在三阴性乳腺癌的标准新辅助化疗后,辅助剂capecitabine的真实数据

Maria Fernanda Imperio Pereira¹, Isabela Panzeri Carlotti Buzatto¹, Hélio Humberto Angotti Carrara¹

¹Department of Gynecology and Obstetrics Ribeirão Preto Medical School Universidade de São Paulo Ribeirão PretoSP Brazil Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia

|August 23, 2024

概括

在新辅助化疗 (NACT) 中添加辅助性capecitabine并没有改善三阴性乳腺癌 (TNBC) 患者的存活率. 需要进一步的研究,以指导这种患者群体的治疗升级.

科学领域:

在瘤学瘤学.
临床癌症研究临床癌症研究
乳腺癌治疗方法乳腺癌治疗方法

背景情况:

新辅助化疗 (NACT) 是三阴性乳腺癌 (TNBC) 的标准,瘤> 1厘米或阳性节点.
在NACT后的病理完整反应 (pCR) 用于指导治疗决策.
在NACT后为没有PCR的TNBC患者添加辅助性capecitabine的益处尚不清楚.

研究的目的:

评估TNBC患者中辅助性capecitabine的实际益处,这些患者在标准NACT后没有达到pCR.
评估残留疾病对TNBC生存结果的影响.
为了确定用capecitabine治疗升级是否改善了这一亚组的生存率.

主要方法:

对接受NACT (2010-2020) 的TNBC患者进行了回顾性队列研究.
从患者记录中收集的临床病理学数据.
进行单变量和多变量分析,随访5年.

主要成果:

包括153名TNBC患者;58.2%患有第三阶段,60.8%高度瘤.
总体PCR率为34.6%. 这是一个很好的结果.
41%的残留疾病患者接受了辅助性capecitabine;没有观察到生存益处 (p=0.52).
实现pCR显著改善了疾病特异性存活率 (DSS) (p<0.0001).
在NACT后的残留疾病与较差的DSS有关.

结论:

这项研究没有发现添加辅助性capecitabine对NACT后残留疾病的TNBC患者的生存益处.
需要进一步调查,以确定残留疾病的TNBC患者的最佳系统治疗升级策略.

关键词:

乳腺新生体的形成.卡佩西塔/治疗用途新辅助疗法是一种新辅助疗法.三重阴性乳腺新生体.

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...